Consensus statement of dienogest as a progestin in contraception and non-contraceptive clinical entities (heavy menstrual bleeding, acne and hirsutism). Narrative review of the literature and recent developments

In: The European Journal of Contraception & Reproductive Health Care · 2026 · pp. 1–13 · doi:10.1080/13625187.2026.2695185 · PMID:42417268 · W7167664064
review OA: hybrid CC0
AI-generated summary by claude@2026-07, 2026-07-11

This narrative review examines dienogest's effects beyond contraception, particularly its therapeutic benefits for heavy menstrual bleeding, acne, hirsutism, and polycystic ovary syndrome.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Combined oral contraceptives (COC)s, besides offering a reliable and safe contraception, offer a variety of non-contraceptive health benefits and therapeutic positive aspects. METHODS: While contraceptive use is the primary indication for COC use, a variety of medical conditions have been added in the summary of product characteristics (SmPC) of these formulations. RESULTS: Dienogest, a 17a-cyanomethyl-17ß-hydroxy-4,9-estradien-3-one progestin is used in different dosage regimes with different oestrogens and with different release forms in contraception and has, depending on the type of COC additional medical treatment indications. CONCLUSIONS: This narrative review will focus on the effects, apart from contraception, of these COCs on female target organs like the uterus and the skin and clinical entities as the polycystic ovarian syndrome (PCOS).

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Source provenance

openalex
last seen: 2026-07-16T11:09:27.693067+00:00
License: CC0 · commercial use OK